Sanofi's SAR444881 tumor trial results posted after early stop; hemophilia study recruits
Sanofi's terminated SAR444881 solid tumor trial posted results, while a UTSW-led hemophilia study naming Sanofi as collaborator is recruiting children in Dallas.
Two Sanofi-linked studies had registry updates dated September 29, 2026.
- SAR444881, a drug also known as BND-22, was tested alone and combined with pembrolizumab, cetuximab, or chemotherapy in a Phase 1/2 trial in advanced solid tumors. The study was terminated early based on strategic sponsor decision not driven by any safety concerns1, with primary and study completion dated 2025-07-02 and results first posted 2026-09-29; enrollment reached 125 participants.
- A University of Texas Southwestern Medical Center observational study, listing Sanofi as a collaborator, is recruiting children with moderate or severe hemophilia A. The study aims to compare differences in the way children with moderate or severe hemophilia A respond when being treated with prophylactic extended half-life factor VIII based replacement therapy (such as Altuviiio) vs non-FVIII based replacement therapy (such as Hemlibra)2, with an estimated enrollment of 60 participants and estimated completion in May 2033.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.